Tag: neovascular age-related macular degeneration

Eye doctor looking into a man's eye
February 23, 2024/Eye Care & Treatment

Faricimab Improves Results for Most Patients on Prior Therapy for nAMD

Switching medications may decrease treatment burden and macular fluid

22-EYE-3438365 CQD-Fluid volatility in nAMD-Ehlers
March 2, 2023/Eye Care & Treatment

Exudative Stability Key to Anti-VEGF Outcome in nAMD

Advanced OCT features may help individualize treatment intervals

22-EYE-3141638 CQD-EYP-1901 with vorolanib for maintenance of nAMD
August 23, 2022/Ophthalmology Research

DAVIO Trial Results: Vorolanib Injection Reduces Treatment Burden for Patients with nAMD

53% of participants didn’t need anti-VEGF for six months or longer

21-EYE- 2468445- CQD – Faricimab in Neovascular
November 18, 2021/Ophthalmology Research

Effect of New Therapy Lasts Longer for Patients with Neovascular Age-Related Macular Degeneration

Faricimab every 16 weeks offers similar benefits as aflibercept every eight weeks


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

July 14, 2021/Eye Care & Treatment

Even Brief Delays in Intravitreal Injection Can Cause Vision Loss

Patients with diabetic eye disease are most affected

October 28, 2020/Eye Care & Treatment

Consequences of Lapse in Anti-VEGF Therapy During the COVID-19 Pandemic

Studies evaluate patients who missed treatments for diabetic macular edema and neovascular age-related macular degeneration

BackPage 1 of 1Next